Volume 6, Issue 5, Pages (November 2002)

Slides:



Advertisements
Similar presentations
Date of download: 11/12/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Retargeting to EGFR Enhances Adenovirus Infection.
Advertisements

Molecular Therapy - Oncolytics
Molecular Therapy - Oncolytics
Volume 5, Issue 3, Pages (March 2002)
Volume 12, Issue 5, Pages (November 2005)
Volume 8, Issue 3, Pages (September 2003)
Mara Curaba, M. Sc. , Magali Verleysen, M. D
Volume 4, Issue 1, Pages (July 2001)
Recombinant mumps virus as a cancer therapeutic agent
Volume 15, Issue 12, Pages (December 2007)
Transgene Expression in the Brain Stem Effected by Intramuscular Injection of Polyethylenimine/DNA Complexes  Shu Wang, Nan Ma, Shujun J. Gao, Hanry Yu,
Volume 3, Issue 5, Pages (May 2001)
Volume 6, Issue 3, Pages (September 2002)
Volume 9, Issue 4, Pages (April 2004)
Volume 13, Issue 6, Pages (June 2006)
Michael I. Ebright, MD, Jonathan S
Volume 22, Issue 1, Pages (January 2014)
Volume 24, Issue 5, Pages (May 2016)
Volume 2, Issue 3, Pages (September 2000)
Volume 18, Issue 11, Pages (November 2010)
VSV-G Envelope Glycoprotein Forms Complexes with Plasmid DNA and MLV Retrovirus-like Particles in Cell-free Conditions and Enhances DNA Transfection 
Volume 5, Issue 2, Pages (February 2002)
Molecular Therapy - Oncolytics
Volume 3, Issue 4, Pages (April 2001)
Incorporation of the B18R Gene of Vaccinia Virus Into an Oncolytic Herpes Simplex Virus Improves Antitumor Activity  Xinping Fu, Armando Rivera, Lihua.
Volume 8, Issue 3, Pages (September 2003)
Volume 9, Issue 6, Pages (June 2004)
Volume 24, Issue 1, Pages (January 2016)
Volume 12, Issue 6, Pages (December 2005)
Molecular Therapy - Oncolytics
In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis
Strong Promoters Are the Key to Highly Efficient, Noninflammatory and Noncytotoxic Adenoviral-Mediated Transgene Delivery into the Brain in Vivo  Christian.
Volume 6, Issue 1, Pages (July 2002)
Volume 23, Issue 4, Pages (April 2015)
Volume 12, Issue 5, Pages (November 2005)
Thomas S. Griffith, Elizabeth L. Broghammer  Molecular Therapy 
Volume 124, Issue 1, Pages (January 2003)
Volume 5, Issue 6, Pages (June 2002)
Volume 6, Issue 5, Pages (November 2002)
Plasmid Delivery in Vivo from Porous Tissue-Engineering Scaffolds: Transgene Expression and Cellular Transfection  Jae-Hyung Jang, Christopher B. Rives,
Volume 20, Issue 5, Pages (May 2012)
Volume 7, Issue 2, Pages (February 2003)
Volume 10, Issue 4, Pages (October 2004)
Volume 12, Issue 2, Pages (August 2005)
Volume 6, Issue 5, Pages (November 2002)
Volume 8, Issue 2, Pages (August 2003)
Sangeet Lal, Corey Raffel  Molecular Therapy - Oncolytics 
Volume 19, Issue 7, Pages (July 2011)
Volume 21, Issue 4, Pages (April 2013)
Volume 12, Issue 6, Pages (December 2005)
Rachel Maddox Schek, Scott J Hollister, Paul H Krebsbach 
Volume 23, Issue 3, Pages (March 2015)
Therapeutic Efficacy of G207, a Conditionally Replicating Herpes Simplex Virus Type 1 Mutant, for Gallbladder Carcinoma in Immunocompetent Hamsters  Kenji.
Volume 4, Issue 4, Pages (October 2001)
Volume 3, Issue 5, Pages (May 2001)
Single-Shot, Multicycle Suicide Gene Therapy by Replication-Competent Retrovirus Vectors Achieves Long-Term Survival Benefit in Experimental Glioma  Chien-Kuo.
Volume 20, Issue 4, Pages (April 2012)
Volume 16, Issue 4, Pages (April 2008)
Molecular Therapy - Methods & Clinical Development
Development of Novel Formulations That Enhance Adenoviral-Mediated Gene Expression in the Lung in Vitro and in Vivo  Maria A. Croyle, Xuan Cheng, Arbans.
Volume 16, Issue 10, Pages (October 2008)
Loss of Transgene following ex vivo Gene Transfer is Associated with a Dominant Th2 Response: Implications for Cutaneous Gene Therapy  Zhenmei Lu, Soosan.
Volume 3, Issue 1, Pages 8-13 (January 2001)
Volume 20, Issue 4, Pages (April 2012)
Volume 3, Issue 5, Pages (May 2001)
Volume 16, Issue 4, Pages (April 2008)
Molecular Therapy - Oncolytics
Arati Sridharan, Chetan Patel, Jit Muthuswamy 
Volume 15, Issue 2, Pages (February 2007)
Volume 12, Issue 5, Pages (November 2005)
Presentation transcript:

Volume 6, Issue 5, Pages 609-614 (November 2002) The Organotypic Multicellular Spheroid Is a Relevant Three-Dimensional Model to Study Adenovirus Replication and Penetration in Human Tumors in Vitro  Jacques Grill, Martine L.M. Lamfers, Victor W. van Beusechem, Clemens M. Dirven, D.Shareen Pherai, Mathijs Kater, Paul Van der Valk, Ronald Vogels, W.Peter Vandertop, Herbert M. Pinedo, David T. Curiel, Winald R. Gerritsen  Molecular Therapy  Volume 6, Issue 5, Pages 609-614 (November 2002) DOI: 10.1006/mthe.2002.0713 Copyright © 2002 American Society for Gene Therapy Terms and Conditions

FIG. 1 Immunohistochemistry for coxsackievirus adenovirus receptor (CAR) on primary tumors and derived spheroids. Frozen sections were stained using an anti-CAR mouse monoclonal antibody raised against the CAR ectodomain and counterstained with H&E. Spheroids were processed after 2 weeks of culture, that is, at the time they are routinely used for experiments. (A) Glioma tumor VU-61. CAR expression is detected in > 50% of the tumor cells with a perinuclear and cytoplasmic distribution. Analysis of the whole-tumor sample showed clear heterogeneity in the intensity of the staining. (B) Glioma spheroid VU-61. A similar pattern of CAR staining is detected as in the primary tumor. (C) Meningioma tumor VU-59. CAR expression is detected in ≈ 50% of the cells. Staining was mostly cytoplasmic. (D) Meningioma spheroid VU-59. Similar CAR expression is found in the spheroids. Note that spheroids conserved the architecture of the tumor they were derived from in both cases. Original magnifications: ×40. Molecular Therapy 2002 6, 609-614DOI: (10.1006/mthe.2002.0713) Copyright © 2002 American Society for Gene Therapy Terms and Conditions

FIG. 2 Transgene expression in spheroids after infection with replication-defective adenovirus. (A) Spheroids prepared from primary glioblastoma multiforme tissue (VU-109) were infected with increasing doses of AdCMVLacZ (106, 107, 108, and 5 × 108 pfu/spheroid) for 24 hours, and X-Gal staining was done on day 1 after infection according to the manufacturer's instructions (β-Gal Staining Set; Boehringer Mannheim, Almere, The Netherlands). En face photographs of the spheroids were taken under light microscopy. The scale bars represent 100 μm. (B) X-gal staining (Beta-Gal Staining Set; Boehringer Mannheim) on a cryosection of a spheroid prepared from primary glioblastoma multiforme tissue (VU-19) was done 24 hours after infection of the spheroid in a virus concentration of 5 × 108 pfu/spheroid AdCMVLacZ. The section was counterstained with H&E. Only the first one or two peripheral layers of the spheroid are infected by the adenovirus as visualized by the expression of the transgene. Scale bars, 100 μm. Molecular Therapy 2002 6, 609-614DOI: (10.1006/mthe.2002.0713) Copyright © 2002 American Society for Gene Therapy Terms and Conditions

FIG. 3 Transgene expression in organotypic multicellular spheroids during the course of propagation of a replication-competent adenovirus. (A) Cryosections of primary glioblastoma spheroids of patient VU-26 were made at 4, 8, and 12 days post infection with AdE1+Luc (5 × 107 pfu/ml) and stained with a new anti-luciferase monoclonal antibody, LUC-Y. (B) Hematoxylin staining of parallel sections demonstrated the presence of necrotic cells due to viral replication in the periphery of the spheroid and viable cells in the core of the spheroid 12 days post infection. (C) For comparison, a section of VU-26 spheroids infected with replication-defective AdCMVLuc was stained for luciferase expression 12 days post infection. Scale bars, 100 μm. Molecular Therapy 2002 6, 609-614DOI: (10.1006/mthe.2002.0713) Copyright © 2002 American Society for Gene Therapy Terms and Conditions

FIG. 4 Dose-dependent oncolysis of organotypic glioma spheroids with a replication-competent adenovirus. Spheroids (n = 7 per group) derived from the glioblastoma tumor of patient VU-65 were infected with increasing concentrations of AdE1+Luc, and viability was measured 10 days later with the WST-1 assay according to the manufacturer's instructions (Roche Diagnostics, Mannheim, Germany). Data are presented as mean ± SEM of the OD450 after subtraction of the background. A significant dose-dependent oncolysis was observed 10 days after infection (P = 0.0001, ANOVA). Dose-dependent oncolysis could also be observed as early as day 6 (data not shown). Molecular Therapy 2002 6, 609-614DOI: (10.1006/mthe.2002.0713) Copyright © 2002 American Society for Gene Therapy Terms and Conditions

FIG. 5 Oncolysis of organotypic multicellular spheroids from five glioblastoma multiforme patients after infection with a replication-competent adenovirus. Spheroids from the tumor of five different patients were infected with 108 pfu/spheroid of AdE1+Luc, and viability was assessed 2 weeks after infection. Results are given as the OD450 value of the WST-1 assay, 24 hours after initiation of the reaction. The graph represents the distribution in percentiles of the values observed for each spheroid (n = 5 to 8 per group), according to Cleveland and Tukey using StatView software. The control groups are shown in white and the treated groups are shown in gray. The boxes represent 50% of the distribution. The horizontal lines represent the medians. The bars encompass 90% of the distribution and the circles represent the extreme values. The following differences in metabolic activity of untreated controls and treated spheroids compared by Student's t-test were observed: P > 0.05 for VU-19 and VU-21, P = 0.02 for VU-33, P = 0.005 for VU-35, and P = 0.002 for VU-65. *P lt; 0.05. Molecular Therapy 2002 6, 609-614DOI: (10.1006/mthe.2002.0713) Copyright © 2002 American Society for Gene Therapy Terms and Conditions